KR100655593B1 - Composition for Liver Protection and Reduction of Serum Ethanol Level - Google Patents
Composition for Liver Protection and Reduction of Serum Ethanol Level Download PDFInfo
- Publication number
- KR100655593B1 KR100655593B1 KR1020040072213A KR20040072213A KR100655593B1 KR 100655593 B1 KR100655593 B1 KR 100655593B1 KR 1020040072213 A KR1020040072213 A KR 1020040072213A KR 20040072213 A KR20040072213 A KR 20040072213A KR 100655593 B1 KR100655593 B1 KR 100655593B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- liver
- alcohol
- present
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 210000004185 liver Anatomy 0.000 title claims abstract description 31
- 210000002966 serum Anatomy 0.000 title 1
- 210000004369 blood Anatomy 0.000 claims abstract description 33
- 239000008280 blood Substances 0.000 claims abstract description 33
- 238000000855 fermentation Methods 0.000 claims abstract description 15
- 230000004151 fermentation Effects 0.000 claims abstract description 15
- 235000011293 Brassica napus Nutrition 0.000 claims abstract description 14
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 claims abstract description 14
- 240000008100 Brassica rapa Species 0.000 claims abstract description 13
- 235000020727 milk thistle extract Nutrition 0.000 claims abstract description 13
- 229940096421 milk thistle extract Drugs 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000012141 concentrate Substances 0.000 claims abstract description 11
- 230000015556 catabolic process Effects 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 238000006731 degradation reaction Methods 0.000 claims abstract description 4
- 241000219495 Betulaceae Species 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 241000207923 Lamiaceae Species 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 abstract description 17
- 231100000234 hepatic damage Toxicity 0.000 abstract description 17
- 230000008818 liver damage Effects 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 235000020687 goji berry extract Nutrition 0.000 abstract description 10
- 230000001684 chronic effect Effects 0.000 abstract description 9
- 230000035622 drinking Effects 0.000 abstract description 6
- 239000002075 main ingredient Substances 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 244000241838 Lycium barbarum Species 0.000 abstract description 5
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 4
- 240000001439 Opuntia Species 0.000 abstract description 4
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 206010036067 polydipsia Diseases 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 235000010841 Silybum marianum Nutrition 0.000 abstract description 3
- 229940107588 barberry extract Drugs 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 241000320380 Silybum Species 0.000 abstract description 2
- 240000002791 Brassica napus Species 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 53
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000003494 hepatocyte Anatomy 0.000 description 10
- 208000019423 liver disease Diseases 0.000 description 9
- 206010019133 Hangover Diseases 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 231100000304 hepatotoxicity Toxicity 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 241001632410 Eleutherococcus senticosus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 240000000643 Alnus japonica Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000269837 Artemisia dubia Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000060924 Brassica campestris Species 0.000 description 1
- 235000005637 Brassica campestris Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 244000286695 Melinis minutiflora var. inermis Species 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241001347459 Prunella vulgaris var. lilacina Species 0.000 description 1
- 244000172730 Rubus fruticosus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- -1 compounds isothiocyanate Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 간장 보호 및 혈중 알코올 분해에 유효한 조성물에 관한 것으로, 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물 또는 밀크씨슬 추출물 중에서 3가지 성분을 주원료로 하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 하는 5가지 유효성분을 함유한 기능성 조성물이다.The present invention relates to a composition effective for the protection of the liver and the degradation of blood alcohol, the main ingredient of the three components from the barberry extract, brown root extract, goji berry extract, alderwood extract, nectar extract or milk thistle extract and turnip concentrate, green bean-rice bran fermentation It is a functional composition containing five active ingredients containing the extract as an auxiliary ingredient.
상기 본 발명의 조성물은 상기 각 성분을 적절한 배합비율로 혼합 사용함으로써 각 성분을 개별적으로 사용했을 때 보다도 상승적인 효과가 있는 것으로, 과음 또는 만성 알코올 섭취에 의한 간 손상을 보호하거나 이들에 의해 손상 받은 간을 치유하는 효과가 매우 우수하며, 또한 음주 후 알코올 대사를 촉진하여 혈중 알코올을 저하시키는 기능이 매우 우수하여, 상기 본 발명의 조성물을 식품 형태로 식, 음용하였을 때 과음 또는 만성 알코올 섭취에 의한 간 손상을 보호하며, 혈중 알코올 수준을 저하시킬 수 있다.The composition of the present invention has a synergistic effect than when each component is individually used by mixing and using the respective components in an appropriate blending ratio, and protects or damages the liver damage caused by excessive drinking or chronic alcohol intake. The effect of healing the liver is very excellent, and the function of promoting alcohol metabolism and lowering blood alcohol after drinking is very excellent. When the composition of the present invention is eaten and consumed in the form of food, It protects liver damage and can lower blood alcohol levels.
간장, 보호, 알코올, 분해, 추출물, 가시오가피, 갈근, 구기자, 오리목, 꿀풀, 밀크씨슬, 생두, 미강, 순무Soy Sauce, Protection, Alcohol, Decomposition, Extract, Prickly Pear, Root, Wolfberry, Alder, Lavender, Milk Thistle, Green Bean, Rice Bran, Turnip
Description
도1은 본 발명의 상대적 GOT, GPT 저하효과를 나타낸 그래프1 is a graph showing the relative GOT, GPT lowering effect of the present invention
도2는 본 발명의 조성물에 의한 혈중 알코올 농도의 변화를 나타낸 그래프Figure 2 is a graph showing the change in blood alcohol concentration by the composition of the present invention
도3은 본 발명의 조성물의 알코올 과량 섭취에 의한 간손상 보호효과를 나타낸 그래프Figure 3 is a graph showing the effect of protecting the liver damage by excessive alcohol intake of the composition of the present invention
도4는 본 발명의 조성물의 만성 알코올 섭취에 의해 유발된 간손상 보호효과를 나타낸 그래프Figure 4 is a graph showing the protective effect of liver damage caused by chronic alcohol intake of the composition of the present invention
본 발명은 간장 보호 및 혈중 알코올 분해에 유효한 조성물에 관한 것으로, 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물 또는 밀크씨슬 추출물 중에서 3가지 성분을 주원료로 하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 하는 5가지 유효성분을 함유한 기능성 조성물이다.The present invention relates to a composition effective for the protection of the liver and the degradation of blood alcohol, the main ingredient of the three components from the barberry extract, brown root extract, goji berry extract, alderwood extract, nectar extract or milk thistle extract and turnip concentrate, green bean-rice bran fermentation It is a functional composition containing five active ingredients containing the extract as an auxiliary ingredient.
상기 본 발명의 조성물은 상기 각 성분을 적절한 배합비율로 혼합 사용함으로써 각 성분을 개별적으로 사용했을 때 보다도 상승적인 효과가 있는 것으로, 과음 또는 만성 알코올 섭취에 의한 간 손상을 보호하거나 이들에 의해 손상 받은 간을 치유하는 효과가 매우 우수하며, 또한 음주 후 알코올 대사를 촉진하여 혈중 알코올을 저하시키는 기능이 매우 우수하여, 상기 본 발명의 조성물을 식품 형태로 식,음용하였을 때 과음 또는 만성 알코올 섭취에 의한 간 손상을 보호하며, 혈중 알코올 수준을 저하시킬 수 있다.The composition of the present invention has a synergistic effect than when each component is individually used by mixing and using the respective components in an appropriate blending ratio, and protects or damages the liver damage caused by excessive drinking or chronic alcohol intake. The effect of healing the liver is very good, and also the function of promoting alcohol metabolism after drinking and lowering the blood alcohol is very good. When the composition of the present invention is eaten or consumed in the form of food, It protects liver damage and can lower blood alcohol levels.
간은 인체에서 가장 큰 장기로서, 간의 주요 기능은 체외에서 유입되거나 체내에서 생성된 각종 물질들을 가공 처리하고 중요한 물질들을 합성 공급하는 것이다. The liver is the largest organ in the human body, and the main function of the liver is to process various substances introduced or produced in the body and to synthesize and supply important substances.
상기 간은 흡수된 단당류 및 포도당을 글리코겐이라는 형태로 간에 저장하고 있다가 필요시 다시 분해하여 내보내는 영양 창고의 역할을 하는 동시에 항상 일정한 혈중 포도당 농도를 유지시킨다.The liver stores the absorbed monosaccharides and glucose in the form of glycogen and serves as a nutrient storehouse where it is decomposed and released again when necessary, while maintaining a constant blood glucose level at all times.
또한 혈액에는 우리 몸에서 중요한 역할을 하는 여러 가지 단백질들이 있는데 이중 약 90%는 간에서 만들어진다. 이 밖에도 간은 해독작용 그리고 면역 기관의 역할 등을 하는데, 우리 몸에 들어온 각종 약물과 해로운 물질은 간에서 해가 적은 물질로 바꾸어 소변 또는 쓸개즙을 통해 배설된다. 특히, 간에는 쿠퍼세포라는 면역세포가 있어서 몸 밖에서 들어오는 세균과 독소 또는 이물질을 식균작용을 통해 분해시켜 몸 밖으로 배출시킨다.There are also a number of proteins in the blood that play an important role in our bodies, of which about 90% are made in the liver. In addition, the liver acts as a detoxification function and immune organs, and various drugs and harmful substances entering our body are converted into less harmful substances in the liver and excreted through urine or bile. In particular, the liver has an immune cell called Cooper cells to break down bacteria and toxins or foreign substances coming out of the body through phagocytosis and to be discharged out of the body.
이렇듯 간은 다양하고 중요한 기능들을 수행하기 때문에 간 기능이 심하게 저하되면 여러 가지 문제가 발생한다. 그러나, 간은 왕성한 재생력을 갖고 있어 75%를 절제해도 4-6 개월 후에는 크기와 기능이 회복된다.As such, the liver performs a variety of important functions, if the liver function is severely degraded, various problems occur. However, the liver has a vigorous regeneration, and even after 75% ablation, size and function are restored after 4-6 months.
간질환은 병이 생기는 근본 원인에 따라 바이러스로 인한 간질환, 과음으로 인한 알코올성 간질환, 약물로 인한 독성 간질환, 간에 지방이 축적되는 지방간, 인체 면역계통의 이상으로 인한 자가면역성 간질환, 독성 물질이 과다하게 쌓여서 생기는 대사성 간질환 등으로 구분된다. Liver diseases include liver disease caused by viruses, alcoholic liver disease caused by excessive drinking, toxic liver disease caused by drugs, fatty liver in which fat accumulates in the liver, autoimmune liver disease caused by abnormalities in the human immune system, and toxicity. It is divided into metabolic liver disease caused by excessive accumulation of substances.
국내에서 만성 간질환의 주 원인은 B형 간염 바이러스이고 C형은 증가하는 추세에 있으며 이러한 바이러스성 간질환에 비해서는 상대적으로 적으나, 근래 알코올 소비량 증가와 함께 습관성 음주로 인한 알코올성 간질환이 상당히 늘고 있다. The main cause of chronic liver disease in Korea is hepatitis B virus and hepatitis C is on the rise, and it is relatively small compared with these viral liver diseases. However, alcoholic liver disease caused by habitual drinking and alcohol consumption is considerably increased recently. It is increasing.
알코올성 간질환은 임상 및 병리학적 소견에 따라 지방간, 알코올성 간염, 알코올성 간경변증 등으로 대별된다. 알코올성 지방간은 습관적으로 음주하는 사람의 90-100%에서 발생되며, 알코올성 간염은 10-35%, 알코올성 간경변증은 8-20%에 서만 발생되는 것으로 알려져 있다. Alcoholic liver disease is classified into fatty liver, alcoholic hepatitis, and alcoholic cirrhosis according to clinical and pathological findings. Alcoholic fatty liver is known to occur in 90-100% of habitual drinkers, alcoholic hepatitis in 10-35%, alcoholic cirrhosis in 8-20%.
체내로 흡수된 알코올은 폐, 소변, 땀으로 10% 정도 배설되며 90%는 간에서 대사된다. 혈액을 통해 간으로 이동한 알코올은 간에서 생성되는 여러 효소(Alcohol Dehydrogenase, Microsomal ethanol oxidizing system, Catalase 등)에 의해 아세트알데하이드로 산화되며 아세트알데하이드는 다시 효소에 의해 신체에 무해한 초산으로 산화된다. Alcohol absorbed into the body is excreted in the lungs, urine and sweat by about 10%, 90% is metabolized in the liver. Alcohol, which is transported to the liver through the blood, is oxidized to acetaldehyde by various enzymes produced by the liver (Alcohol Dehydrogenase, Microsomal ethanol oxidizing system, Catalase, etc.), and acetaldehyde is again oxidized to acetic acid, which is harmless to the body by the enzyme.
알코올 산화에 의해 생성되는 대사산물인 아세트알데하이드는 반응성이 강한 독성물질로 단백질과 결합하여 효소 활성 저해, 지질과 산화의 증가로 미토콘드리아에 손상, 글루타치온 결핍 초래 및 피리독신, 비타민 A, 아연 및 셀레늄 등의 결핍을 초래, 투불린 중합 저해에 의한 단백질 분비 및 이동 저해 등을 발생하는 간 손상을 유발하는 주요 인자로 지적되고 있다. 또한 아세트알데하이드에 의한 유리기(free radical) 생성은 간의 콜라겐(collagen) 합성을 촉진시키므로, 이는 만성적인 알코올 섭취자에 있어 간 섬유화(간경변)의 원인이 되는 것으로 보고되고 있다. Acetaldehyde, a metabolite produced by alcohol oxidation, is a highly reactive toxic substance that binds to proteins, inhibits enzyme activity, damages mitochondria due to increased lipids and oxidation, causes glutathione deficiency, and pyridoxine, vitamin A, zinc and selenium. It has been pointed out as a major factor causing liver damage that causes deficiency, inhibits protein secretion and migration by inhibiting tubulin polymerization. In addition, the production of free radicals by acetaldehyde promotes collagen synthesis in the liver, which is reported to cause liver fibrosis (cirrhosis) in chronic alcohol intake.
이를 위하여 알코올 대사 억제제, 알코올 대사 촉진제, 알코올 분해효소 등과 같은 많은 소재들이 개발 또는 그 조성물들이 활용되어 왔으며, 예로 대한민국 특허등록 제0178696호에는 간보호 및 간장질환 치료용 의약조성물, 공개특허 제2001-0050333호 숙취해소 및 간기능개선용 한방생액제의 음료와 그 제조방법, 특허등록 제0345798호 지구자나무, 오리나무, 칡 혼합물을 이용한 숙취 해소 기능성 식품 및 이의 제조방법, 공개특허 제2002-0021980호 알콜대사 향상제 및 간장애 저 감제, 공개특허 제 2002-0004193 알콜 흡수 억제제를 함유한 숙취 제거 및 간장 보호용조성물, 공개특허 제2003-0005127호 지구자와 오리나무를 주제로 한 건강식품이 있다.To this end, many materials such as alcohol metabolism inhibitors, alcohol metabolism promoters, alcohol degrading enzymes, and the like have been developed or utilized in the composition thereof. For example, Korean Patent Registration No. 0178696 discloses a pharmaceutical composition for liver protection and liver disease treatment. No. 0050333 Hangover drink and its manufacturing method for the hangover remedy and liver function improvement, Patent registration No. 0345798 Hangover functional foods using earthworm, alder, 칡 mixture and its manufacturing method, Korean Patent No. 2002-0021980 Alcohol metabolism enhancer and liver disorder lowering agent, hangover removal and soy sauce protective composition containing alcohol absorption inhibitor, there is a health food based on the earth and alder.
또한, 특허등록 제0403720호 헛개나무 어린 가지로부터 분리된 간독성, 숙취 및 피로해소 활성을 갖는 저급알콜 불용성 추출 분획 및 다당체물질 및 이를 함유한 조성물, 특허등록 제0403721호 헛개나무로부터 분리된 간독성 및 숙취 해소 활성을 갖는 저급알콜 불용성 추출 분획 및 다당체 물질 및 이를 함유한 조성물, 특허등록 제0403722호 헛개나무 목질부로부터 분리된 간 보호활성을 갖는 저급알콜 불용성 추출물, 이로부터 분리된 다당체 및 이를 함유하는 조성물, 공개특허 제2004-0052930호 숙취해소용 조성물 및 이를 유효성분으로 함유하는 숙취해소제 등이 있으나, 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물 중에서 3가지 성분을 주원료로 하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 하는 5가지 유효성분을 함유하는 기술은 아직까지 미미한 실정이다.In addition, patent registration No.0403720 hepatotoxicity, hangover and anti-fatigue activity of low alcohol insoluble extract fractions and polysaccharides and compositions containing the same, hepatotoxicity and hangover isolated from No. 403721 Lower alcohol insoluble extract fraction and polysaccharide material having relieving activity and composition containing same, low alcohol insoluble extract having hepatoprotective activity isolated from woody part of patent document No. 0438522, polysaccharide isolated from it and composition containing same, There is a hangover composition and hangover releasing agent containing the same as an active ingredient, hangangpi extract, brown root extract, goji berry extract, alderwood extract, nectar extract, milk thistle extract is the
따라서, 본 발명에서는 이러한 점을 감안하여 이루어진 것으로, 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물 중에서 3가지 성분을 주원료로 하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 하는 5가지 유효성분을 함유하여 알코올 및 약물에 의한 간 손상을 보호 또 는 치유하는 기능을 갖는 동시에 음주 후 혈중 알코올을 저하시키는 기능을 갖으며, 상기 각 성분을 적절한 배합비율로 혼합 사용함으로써 각 성분을 개별적으로 사용했을 때 보다도 상승적인 효과가 있는 새로운 형태의 간장 보호 및 혈중 알코올 분해에 유효한 조성물을 제공하고자 한다.
Therefore, the present invention was made in view of this point, the main components of the thorn oak extract, brown root extract, goji berry extract, alderwood extract, nectar extract, milk thistle extract as a main raw material and turnip concentrate, green bean-rice bran fermentation extract It contains five active ingredients to protect or heal liver damage caused by alcohol and drugs, and also to lower blood alcohol after drinking. It is intended to provide a new form of hepatic protection and blood alcohol breakdown that has a synergistic effect than when used individually.
본 발명은 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물 중에서 3가지 성분을 주원료로 하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 하는 5가지 유효성분을 함유하는 것을 특징으로 한다.The present invention is to contain five active ingredients as the main raw material and the turnip concentrate, green soybean-rice bran fermentation extract as a main ingredient among the thorn extract, goose root extract, goji berry extract, alderwood extract, nectar extract, milk thistle extract It features.
좀더 구체적으로는 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물 중에서 3가지 성분이 주원료로 52중량% 차지하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 28중량%을 차지하고 나머지는 물로 이루어진 간장 보호 및 혈중 알코올 분해에 유효한 조성물이다.More specifically, among the thorny opi extract, brown root extract, goji berry extract, alderwood extract, nectar extract, milk thistle extract, three components accounted for 52% by weight as the main raw material, turnip concentrate, green bean-rice bran fermentation extract as 28% by weight. The remainder are compositions that are effective in protecting liver from liver and decomposing blood alcohol.
여기서, 상기 가시오가피(Eleutherococcus senticosus)는 드릅나무과로 siberian ginseng이라고 알려져 있을 정도로 약효가 우수한 약용식물로, 한방에서는 여름에서 가을 사이에 뿌리와 나무껍질을 말려서 양위, 관절류머티즘, 요통, 퇴행성관절증후군, 수종, 각기, 타박상 등에 처방하여왔다.Here, Eleutherococcus senticosus ( Eleutherococcus senticosus) is a medicinal plant with excellent medicinal effects that is known as siberian ginseng as an elmaceae , in oriental medicine by drying roots and bark between summer and autumn. Prescribed, each, bruises.
상기 갈근은 콩과에 속하는 다년생 덩굴로 뿌리를 약용 및 식용으로 이용하는데, 한방에서는 고혈압, 관상동맥경화증, 협심증, 노인성 당뇨에 이용되고 있다. 또한 갈근의 플라보노이드(flavonoid)는 알코올 분해효소(alcohol dehydrogenase)와 미토콘드리얼 디하이드로게네이즈(mitochondrial dehydrogenase)의 방해제로 알려져 있으며, 지질과산화 억제, 항산화 효과, 그리고 보간작용이 있다The root is a perennial vine belonging to the legumes medicinal and edible root, which is used in herbal medicine for hypertension, coronary arteriosclerosis, angina pectoris, senile diabetes. Flavonoids of the roots are also known as inhibitors of alcohol dehydrogenase and mitochondrial dehydrogenase, and have lipid peroxidation inhibitory, antioxidant and interpolation effects.
상기 구기자는 가지과에 속하는 낙엽 넝쿨 관목으로 과일을 구기자(Lycii fructose), 근피를 지골피(Lycii cortex), 잎을 구기엽(Lycii folium)이라 한다. 한방에서 보약재로서 허약, 만성소모성 질병, 신장 및 간의 보호작용 등 여러 가지 질병의 예방 및 치료에 사용되어 왔다. 또한 혈당과 콜레스테롤의 강하작용, 혈압강하작용 및 간조직 손상 보호작용을 나타낸다(정진섬, 신민교. 1990. 도해향약 대사전. p.86-828).The goji berry is a deciduous vine shrub belonging to the branch family, fruit is called Lycii fructose , the root is called Lycii cortex , and the leaves are called Lycii folium . It has been used for the prevention and treatment of various diseases such as weakness, chronic wasting disease, kidney and liver protection as herbal medicine. It also lowers blood sugar and cholesterol, lowers blood pressure, and protects liver tissue (Jin, Jin-Sum, Shin, Min-Kyo.
여기서, 상기 오리목(Alnus japonica Steud.)은 자작나무과에 딸린 낙엽큰키나무로서 유리목(楡里木) 또는 적양(赤楊)이라고도 하며 중국에서는 다조(茶條)라고 한다. 반드시 깊은 산속에 있는 토종 조선오리나무라야 술독을 풀고 간을 보호하는 효과가 있다고 알려져 있다. 주요 성분은 탄닌, 트리테르페노이드인 타락세롤, 베툴린산, 정유 등이다. 이 나무는 간염·간경화·지방간 등 갖가지 간질환에 치료효과가 뛰어난 약목(藥木)으로 알려져 있다.Here, the alder ( Alnus japonica Steud.) Is a deciduous algae tree in the birch family, also known as glass tree (楡 里木) or red sheep (赤 楊), and is called tea in China. It is known that the native Korean duck tree in the deep mountains must be used to loosen the poison and protect the liver. The main ingredients are tannins, the triterpenoids taraxerol, betulinic acid and essential oils. This tree is known as a herb that has excellent therapeutic effect against various liver diseases such as hepatitis, cirrhosis and fatty liver.
상기 꿀풀(Prunella vulgaris var. lilacina Nakai)은 여름에 과수가 반쯤 시들면 채취하여 햇볕에 말려 약재로 사용하여온 무독한 한방 생약이다. 한방에서는 만성적인 종기, 두창 급성 유선염 및 임파선 결핵 등에 이용되어 왔다. 주요 성분으로 올레아놀린산(oleanolic acid), 우르솔린산(ursolic acid)등의 사포닌류와 카로틴(carotine), 비타민 C(vitamin C) 비타민 K(vitamin K), 탄닌(tannin), 카페 인산(caffeic acid), 클로르제닌산(chlorogenic acid) 등이 알려져 있다[한국유용식물자원 연구총람, 한국화학연구소 pp.480-482(1988)].The nectar ( Prunella vulgaris var. Lilacina Nakai) is a toxic herbal medicine that has been harvested when fruit trees wither in half in summer and dried in the sun and used as medicinal herbs. In oriental medicine, it has been used for chronic boils, acute mastitis and lymph node tuberculosis. Major ingredients include saponins such as oleanolic acid and ursolic acid, carotene, vitamin C, vitamin K, tannin, and caffeic acid. , Chlorogenic acid and the like are known [Korea Plant Research Resources Review, Korea Research Institute of Chemical Technology, pp.480-482 (1988)].
상기 밀크씨슬(Silybum marianum (L.) Gaertner)은 국화과 식물로 1년초 또는 2년생의 지중해지방 원산의 식물로서 전통적으로 유럽에서 약용식물로 널리 사용되어온 식물이다. 오늘날은 이 식물의 정제추출물질인 실리마린(silymarin) 또는 그 주성분인 실리빈(silybin)이 중독성 간손상, 만성 염증성 간질환 바이러스성 간염 및 간경변에 대한 보조치료제로 사용중에 있다. 이외에도 단백질 합성증가에 의한 간의 재생, 간손상시 생성되는 루코트리엔(leukotriene)과 염증반응성 프로스타글란딘(inflammatory prostaglandin)의 형성을 억제, 강력한 항산화효과, 과음 후 해독과정에 필수 성분인 글루타치온(glutachione)의 결핍 예방 등의 다양한 생리활성을 나타낸다. The milk thistle ( Silybum marianum (L.) Gaertner) is an asteraceae plant that is native to the Mediterranean region of 1 year or 2 years, and has been widely used as a medicinal plant in Europe. Today, the plant's purified extract, silymarin, or its main ingredient, silybin, is being used as an adjuvant treatment for toxic liver damage, chronic inflammatory liver disease, viral hepatitis, and cirrhosis. In addition, hepatic regeneration by increasing protein synthesis, inhibits the formation of leukotriene and inflammatory prostaglandin produced during liver damage, strong antioxidant effects, glutathione, an essential ingredient for detoxification after drinking It shows various biological activities such as prevention of deficiency.
상기 생두-미강발효 추출물은 볶지 않은 커피 원두와 곡물을 미생물을 이용한 발효공법에 의해서 발효추출한 천연물로서 항산화 작용과 유해산소 제거 효과가 있는 인산 이노시톨(inositol phosphate)과 폴리페놀(polyphenol), 아미노산(amino acid), 펩타이드(peptide)가 함유된 기능성 식물발효추출물로서 인체에 유해한 유해산소를 제거하여 DNA 손상(암 발생원인)방지, 불포화지방산의 과산화방지 효과, ACE 저해작용으로 인한 고혈압 방지 작용 등의 효과가 있다. The green bean-rice bran fermentation extract is a natural product obtained by fermentation of unroasted coffee beans and grains by a fermentation method using microorganisms. Inositol phosphate, polyphenols, and amino acids (inositol phosphate) having an antioxidant action and harmful oxygen removal effect It is a functional plant fermentation extract containing acid) and peptide, which removes harmful oxygen that is harmful to the human body to prevent DNA damage (cause of cancer), to prevent peroxidation of unsaturated fatty acids, and to prevent hypertension due to ACE inhibition. There is.
또한, 상기 순무(Brassica campestris L. var. rapifera)의 유효성분으로 황을 함유한 화합물인 이소타이오사이안산염(Isothiocyanate), 다이설파이드(disulfide), 설포라판(sulforaphane) 등이 있다. 순무의 매운 맛을 내는 이소시아 네이트(isocyanate)는 오래 전부터 항암 성분으로 알려져 왔으며, 동물실험에선 식도암, 간암, 폐암, 대장암을 예방하는 효과가 입증되었다. 최근 국내 동물실험에서 간암, 간경화 증세를 경감시키는 효과가 있는 것으로 보고되고 있다. In addition, as an active ingredient of the turnip ( Brassica campestris L. var. Rapifera ), there are sulfur-containing compounds isothiocyanate, disulfide, and sulfoaphane. The spicy flavor of turnips has long been known as an anticancer ingredient, and animal studies have proven its effectiveness in preventing esophageal, liver, lung and colon cancers. Recently, animal studies in Korea have been reported to reduce the effects of liver cancer and cirrhosis.
이하, 본 발명의 구성을 실시예를 통하여 좀더 상세히 설명한다.Hereinafter, the configuration of the present invention will be described in more detail by examples.
실시예Example
먼저, 오리목 추출물은 건조된 오리목의 목질 및 수피 100 g을 100℃ 끓는 물 1000 g 넣어 3시간 동안 추출한 후 추출액을 5 ㎛ 여과지로 여과하여 최종적으로 오리목 추출물 500 g을 얻었다. First, the alder extract was extracted with 100 g of boiled water at 100 ° C. in 100 g of dried alder wood and bark for 3 hours, and then the extract was filtered through a 5 μm filter paper to finally obtain 500 g of the alder extract.
가시오가피와 갈근 추출물은 건조된 가시오가피와 갈근 100 g을 100℃ 끓는 물 1000 g 에 넣어 3시간 동안 추출한 후 추출액을 5 ㎛ 여과지로 여과하여 최종적으로 가시오가피와 갈근 추출물 500 g을 얻었다.Prickly pear and root extract were put into 100 grams of dried thorny vine and root and extracted in 1000 g of boiling water at 100 ° C. for 3 hours, and then the extract was filtered through 5 μm filter paper to finally obtain 500 g of thorny stem and root extract.
꿀풀 추출물은 건조된 꿀풀 50 g을 100℃ 끓는 물 1000 g에 넣어 2시간 동안 추출한 후 추출액을 400 메쉬(mesh)로 여과하여 최종적으로 꿀풀 추출물 600 g을 얻었다. After extracting 50 g of dried honey grass into 1000 g of boiling water at 100 ° C. for 2 hours, the extract was filtered through a 400 mesh to finally obtain 600 g of honey leaf extract.
구기자는 건조된 구기자 100 g을 100℃ 끓는 물 1000 g에 넣어 2시간 동안 추출한 후 추출액을 400 메쉬(mesh)로 여과하여 최종적으로 구기자 추출물 600 g을 얻었다.The wolfberry was put 100 g of dried wolfberry in 1000 g of boiling water at 100 ℃ extracted for 2 hours, and then the extract was filtered through a 400 mesh (600 mesh) to finally obtain 600 g of wolfberry extract.
또한, 밀크씨슬 추출물(TGS, Japan)은 분말상태로 총 플라보노이드 함량 80% 이상인 것을 시중에서 구입하여 사용하고, 생두-미강발효 추출물(Toyo Hakko, Japan)은 액상인 것을 시중에서 구입하여 사용하였으며, 순무 농축액[(주)강화명품]은 액상(35 oBrix)인 것을 시중에서 구입하여 사용하였다.In addition, milk thistle extract (TGS, Japan) was purchased in the market that the total flavonoid content of more than 80% in powder form, and green soybean-rice bran fermentation extract (Toyo Hakko, Japan) was purchased from the market used liquid , Turnip concentrate [Ganghwa Co., Ltd.] was used as a liquid (35 o Brix) commercially available.
이와 같이하여 얻어진 각 성분을 혼합 교반하되, 전체 중량에 대하여 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물 또는 밀크씨슬 추출물 중에서 3가지 성분이 주원료로 52중량% 차지하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 28중량%을 차지하고 나머지는 물 20.0% 함유된 본 발명의 간장 보호 및 혈중 알코올 분해에 유효한 조성물(Y-MIX로 명칭)을 얻었다.The components obtained in this way are mixed and stirred, but the three components are 52% by weight as the main raw material among the barberry extract, brown root extract, goji berry extract, alderwood extract, nectar extract or milk thistle extract with respect to the total weight. A composition (named Y-MIX) effective for protecting the liver and blood alcohol degradation of the present invention containing 28% by weight of rice bran fermented extract as an auxiliary material and 20.0% of water contained the rest.
이하, 시험예를 통하여 본 발명을 더욱 상세히 설명한다. Hereinafter, the present invention will be described in more detail with reference to test examples.
본 발명의 시험예에 사용한 실험동물로는 5주령의 스프라그-돌리(Sprague-Dawley, SD)계 웅성 쥐(대한 바이오링크 주식회사)를 실온 25±1℃, 습도 50±5% 일정한 조건에서 고형사료(CJ 주식회사 제품)로 1주간 예비사육한 다음 시험용으로 하였다.The experimental animals used in the test examples of the present invention were 5 weeks old Sprague-Dawley (SD) male rats (Korea Biolink Co., Ltd.) at room temperature 25 ± 1 ° C. and
시험예 1(사염화 탄소에 의한 랫트 간세포의 보호)Test Example 1 (Protection of Rat Hepatocytes by Carbon Tetrachloride)
본 발명의 조성물 성분을 각각 단독 또는 혼용투여시 사염화탄소에 대한 실험동물의 간세포 보호효과를 알아보기 위하여 다음과 같이 실험을 하였다. 쥐 간세포의 분리 및 배양은 Berry와Friend의 방법[High-yield preparation of isolated rat liver parenchymal cell. J. Cell. Biol. 43:506-520 (1969)]을 변형하여 다음과 같이 시행하였다. In order to determine the effect of protecting the hepatocytes of the experimental animals against carbon tetrachloride when the composition components of the present invention were administered alone or in combination, the following experiments were carried out. Isolation and culture of rat liver cells were performed by Berry and Friend [High-yield preparation of isolated rat liver parenchymal cell. J. Cell. Biol. 43: 506-520 (1969)].
(랫트의 간세포 분리)(Isolation of Liver Cells from Rats)
랫트를 우레탄(urethane, 1 g/kg)으로 마취한 후 복부를 70%(v/v) 알코올로 소독하였다. 복부의 중앙선을 복개하고 양측을 자른 후 간 문맥에 20 게이지 카테터(gauge catheter)를 삽관하여 행크 밸런스 솔트 용액[Hanks' Balance Salt Solution(HBSS), GIBCO]을 15-20 ml/min의 유속으로 관류시키면서 하대정맥을 신정맥 아래에서 잘라 혈액을 제거하였다. 약 10-20분 후 0.05-0.06%(w/v)의 콜라게나제[collagenase(Sigma)]가 첨가된 행크 밸런스 솔트 용액을 관류시키면서 하대정맥을 묶고 상대정맥에 20 게이지 카테터(gauge catheter)를 삽관하여 간조직을 통과한 과량의 소화액은 빠져 나오게 하였다. 간이 부풀어오를 정도로 20분간 계속 행크 밸런스 솔트 용액을 관류시킨 후 간을 행크 밸런스 솔트 용액(50 ml)으로 옮기고 멸균된 가위로 캡슐(capsule)을 파괴하였다. 간세포를 유리시키고 멸균된 거즈(gauze)로 여과하였다. 여액을 1,500 rpm에서 3분간 2회 원심분리하여 간세포를 세척한 후 우태혈청[Fetal Bovine Serum(Gibco)] 10%, 페니실린-스트렙토마이신[Penicillin-Streptomycin(Gibco)] 1%, 펀지존[Fungizone(Gibco)] 2.5 ml/500 ml, 그리고 글루타민[L-Glutamin(Sigma)] 200 mM 첨가된 윌리엄 배지 E[Williams' Media E(1X, GIBCO)]로 현탁하였다. 세포의 생존율은 트리판 블루(trypan blue)(GIBCO)로 희석하여 혈구계수기(haematometer)로 계수하였다. Rats were anesthetized with urethane (urethane, 1 g / kg) and then the stomach was disinfected with 70% (v / v) alcohol. After the abdomen's central line was cut and both sides were cut, a 20 gauge catheter was inserted into the hepatic portal vein to perfuse Hanks' Balance Salt Solution (HBSS, GIBCO) at a flow rate of 15-20 ml / min. While the inferior vena cava was cut under the renal vein to remove blood. After about 10-20 minutes, the inferior vena cava is added to the relative vein while perfused with a Hank balance salt solution containing 0.05-0.06% (w / v) collagenase (Sigma). Intubation caused excess fluid to pass through the liver tissue. The Hank balance salt solution was allowed to continue flowing through the Hank balance salt solution for 20 minutes to cause the liver to swell, and then the capsules were broken with sterile scissors. Hepatocytes were freed and filtered with sterile gauze. The filtrate was centrifuged twice at 1,500 rpm for 3 min to wash the hepatocytes, followed by 10% fetal bovine serum (Gibco), 1% penicillin-streptomycin (Gibco), and fungi zone (Fungizone). Gibco)] 2.5 ml / 500 ml, and glutamine [L-Glutamin (Sigma)] 200 mM added William medium E [Williams' Media E (1X, GIBCO)]. Cell viability was diluted with trypan blue (GIBCO) and counted with a haematometer.
(랫트 간세포의 배양 및 사염화탄소 독성 유발)(Cultivation of rat liver cells and induction of carbon tetrachloride toxicity)
간세포를 윌리엄 배지 E에 1.0 x 106 cells/ml이 되도록 희석하고 20㎍의 랫트 테일 콜라겐[rat tail collagen (Sigma)]으로 미리 코팅된 24 웰 플레이트에 0.5 ml 씩 분주하였다. 37℃, 5% CO2/95% 배양기에서 4시간 배양한 후 새 배지로 교환하여 부착하지 못하고 손상되거나 죽은 세포를 제거하였다. 새 배지로 교환 후 사염화탄소를 최종농도가 5 mM이 되도록 간세포 현탁액에 첨가하여 독성을 유도하고 동시에 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물, 생두·미강 발효 추출물, 순무 농축액과 본 발명의 조성물을 500 mg/ml를 첨가하였다. 12시간 37℃, 5% CO2/95% 배양기에서 배양한 후 간세포 배양액을 취하여 10,000 rpm에서 3분간 원심분리한 다음 상등액내 GOT 및 GPT 함량을 PRIME(BPC BioSED srl, Italy)을 이용하여 UV-Rate method에 의해 측정하였다. 상대적 GOT 및 GPT 저하효과(Relative Protection of GOT and GPT) (%)(강현정, 이은주, 성상현, 김영중, 송은숙, 박미정, 이흠숙. 2003. 쑥갓의 간독성 보호작용. 한국식품과학회지 35:138-143)는 아래와 같이 측정하였다. Hepatocytes were diluted to 1.0 × 10 6 cells / ml in William Medium E and 0.5 ml aliquoted into 24 well plates precoated with 20 μg rat tail collagen (Sigma). After 4 hours of incubation at 37 ° C. in a 5% CO 2 /95% incubator, the cells were replaced with fresh medium to remove adherent, damaged or dead cells. After exchange with fresh medium, carbon tetrachloride was added to the hepatocyte suspension to a final concentration of 5 mM to induce toxicity. mg / ml was added. After incubation for 12 hours at 37 ° C, 5% CO 2 /95% incubator, hepatocyte culture medium was taken, centrifuged at 10,000 rpm for 3 minutes, and the GOT and GPT contents in the supernatant were measured using UV- It was measured by the rate method. Relative Protection of GOT and GPT (%) (Kang Hyun-Jung, Eun-Joo Lee, Sang-Hyun Sung, Young-Joong Kim, Eun-Sook Song, Mi-Jung Park, Heum-Sook Lee. 2003. Protection of Liver Toxicity of Mugwort. Was measured as follows.
상대적 GOT 저하효과(Relative Protection of GOT) (%)Relative Protection of GOT (%)
= 100 ×[(GOT reference - GOT sample]/[(GOT reference - GOT control) = 100 × [(GOT reference-GOT sample] / [(GOT reference-GOT control)
GOT reference : 사염화탄소만을 첨가한 쥐 간세포 배양액 시료의 GOT 수치GOT reference: GOT level of rat hepatocyte culture medium containing carbon tetrachloride only
GOT sample : 사염화탄소와 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물, 순무 농축액, 생두-미강 발효 추출물 또는 본 발명의 조성물을 각각 첨가한 쥐 간세포 배양액 시료의 GOT 수치GOT sample: GOT values of carbon tetrachloride and bramble extract, root root extract, goji berry extract, alder extract, nectar extract, milk thistle extract, turnip concentrate, green soybean-rice bran fermentation extract or rat hepatocyte culture sample to which the composition of the present invention was added
GOT control : 사염화탄소를 첨가하지 않은 쥐 간세포 배양액 시료의 GOT 수치GOT control: GOT level of rat hepatocyte culture medium without carbon tetrachloride
상대적 GPT 저하효과(Relative Protection of GPT) (%)는 위 식에서 GOT 수치 대신에 GPT 수치로 계산하였다.Relative Protection of GPT (%) was calculated as GPT instead of GOT.
그 결과를 도1에 나타내었으며, 도면에서와 같이, 본 발명의 조성물은 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물, 순무 농축액, 생두-미강 발효 추출물을 개별적으로 사용했을 때 보다도 상승적인 효과가 있음을 알 수 있다.The results are shown in Figure 1, as shown in the drawing, the composition of the present invention, prickly pear extract, brown root extract, goji berry extract, Alderwood extract, Lamiaceae extract, milk thistle extract, turnip concentrate, green bean-rice bran fermentation extract individually It can be seen that there is a synergistic effect than when used.
시험예 2(조성물의 혈중 알코올 저하)Test Example 2 (lower blood alcohol in the composition)
본 발명의 조성물 투여시 혈중 알코올 저하효과를 다음과 같이 동물실험을 하였다. 음성대조군과 양성대조군에는 2주간 PBS(Phosphate buffered saline)를 5 ml/kg B.W. 강제경구 투여하였고, 조성물군에는 본 발명의 조성물을 5 ml/kg B.W. 2주간 투여하였으며, 각군은 5마리로 하였다. 시험 15일째에 음성대조군과 양성대조군에는 PBS를, 조성물군에는 본 발명의 조성물을 각각 5 ml/kg B.W. 투여한 후 30분이내에 양성대조군과 조성물군에 22% 알코올 용액으로 알코올을 4 g/kg B.W. 강제경구 투여하였다. 알코올 투여 후 일정시간이 경과한 후 미정맥으로부터 헤파 린이 처리된 모세관으로 100 ㎕의 혈액을 취하고 여기에 1 ml의 다이클로로메탄(dichloromethane)(Sigma)을 가하고 강하게 교반한 후 소량의 무수 Na2SO4를 처리하여 수분을 제거하고 여과하여 혈액내 알코올 함량 분석에 사용하였다. 알코올 투여 후 시간별로 채혈하여 혈중 알코올의 양을 측정하였다. 혈액내 알코올 함량은 개스크로마토그래피(Hewlett Packard HP6890, GC)를 사용하였으며, 시료는 자동시료주입기(HP G1512A autosampler)를 이용하여 GC에 주입하였다. 검출기는 불꽃이온화검출기(FID)를 사용하였고 이동상 기체로 질소를 사용하였다. 분석에 사용한 컬럼(column)은 DB-Wax(30 m ×0.25 mm ×0.15 ㎛; Agilent)이었으며, 분석조건은 injector 온도가 200℃, 온도프로그래밍(temperature programing)으로 55℃에서 2분간 유지하고, 10℃/min씩 증가시켜 70℃에서 4분간 유지시켰다. 내부표준 물질로 에틸아세데이트(ethyl acetate)를 사용하였다.Animal administration of the blood alcohol lowering effect when the composition of the present invention was administered as follows. Negative control group and positive control group were administered 5 ml / kg BW forced oral PBS (Phosphate buffered saline) for 2 weeks, the composition group was administered the composition of the
그 결과를 도2에 나타내었으며, 도면에서와 같이, 본 발명의 조성물은 대조군에 비하여 우수한 혈중 알코올 저하능을 나타냈다.The results are shown in FIG. 2, and as shown in the drawing, the composition of the present invention showed excellent blood alcohol lowering ability as compared to the control group.
시험예 3(조성물의 과량 알코올 섭취에 의해 유발된 간손상 보호효과)Test Example 3 (protective effect of liver damage caused by excessive alcohol intake of the composition)
본 발명의 조성물 투여시 과량 알코올 섭취에 의해 유발된 간독성에 대한 간보호 효과를 알아보기 위해 다음과 같이 동물실험을 하였다. 음성대조군과 양성대조군에는 PBS(Phosphate buffered saline)를 5 ml/kg B.W. 2주간 강제경구 투여하였고, 조성물군에는 본 발명의 조성물을 5 ml/kg B.W. 2주간 투여하였으며, 각군은 5마리로 하였다. 시험 15일째에 음성대조군과 양성대조군에는 PBS를, 조성물군에는 본 발명의 조성물을 각각 5 ml/kg B.W. 투여한 후 30분이내에 양성대조군과 조성물군에 22% 알코올 용액으로 알코올을 3 g/kg B.W. 강제경구 투여하였다. 알코올 투여 6시간 후에 심장 채혈을 하여 혈액내 GOT, GPT, 그리고 Bilirubin의 함량(IU/L)을 혈액분석장치(automatic analyzer 767, Hitachi, Tokyo, Japan)을 이용하여 측정하였으며, 부검한 후 간조직을 관찰하여 병리학적 증상을 숫자로 표현한 간활성지수[Modified Hepatic Activity Index(Nakaji, M., Hayashi, Y., Ninomiya, T., Yano, Y., Yoon, S., Seo, Y., Nagano, H., Komori, H., Hashimoto, K., Orino, A., Shirane, H., Yokozaki, H., Kasuga, M. 2002. Histological grading and staging in chronic hepatitis: its practical correlation. Pathol. Int. 52:683-690)]를 측정하였다.In order to determine the hepatoprotective effect on hepatotoxicity caused by excessive alcohol intake when administering the composition of the present invention, animal experiments were carried out as follows. Negative control and positive control group were treated with PBS (Phosphate buffered saline) 5 ml / kg B.W. Forced oral administration was performed for 2 weeks, and the composition group contained 5 ml / kg B.W. Two weeks, each group was five. On day 15 of the test, 5 ml / kg B.W. Within 30 minutes after administration, 3 g / kg B.W. alcohol was added to the positive control and composition groups with 22% alcohol solution. Forced oral administration. After 6 hours of alcohol administration, heart blood was collected and blood GOT, GPT, and Bilirubin contents (IU / L) were measured using a blood analyzer (automatic analyzer 767, Hitachi, Tokyo, Japan). Modified Hepatic Activity Index (Nakaji, M., Hayashi, Y., Ninomiya, T., Yano, Y., Yoon, S., Seo, Y., Nagano) , H., Komori, H., Hashimoto, K., Orino, A., Shirane, H., Yokozaki, H., Kasuga, M. 2002.Histological grading and staging in chronic hepatitis: its practical correlation.Pathol.Int 52: 683-690).
그 결과를 도3에 나타내었으며, 본 발명의 조성물의 우수한 간손상 보호효과를 알 수 있다.The results are shown in Figure 3, it can be seen the excellent liver damage protection effect of the composition of the present invention.
시험예 4(조성물의 만성 알코올 섭취에 의해 유발된 간손상 보호효과)Test Example 4 (protective effect of liver damage caused by chronic alcohol intake of the composition)
본 발명의 조성물 투여시 만성 알코올 섭취에 의해 유발된 간손상 보호효과를 알아보기 위하여 다음과 같이 동물실험을 하였다. 음성대조군과 양성대조군에는 1주간 PBS(Phosphate buffered saline)를 5 ml/kg B.W. 강제경구 투여하였으며, 조성물군에는 본 발명의 조성물을 5 ml/kg B.W. 1주간 투여하였다. 시험 1일, 4일, 7일째에 PBS 또는 Y-MIX 투여 후 30분 이내에 양성대조군과 조성물군에 22% 알코올 용액으로 알코올을 2 g/kg B.W. 강제경구 투여하였다. 시험 7일째에 알코올을 투여한 후 그 다음날 심장채혈을 하여 혈액내 GOT, GPT, 그리고 Bilirubin의 함량을 측정하였으며, 부검한 후 간조직을 관찰하여 병리학적 증상을 숫자로 표현한 간활성지수를 측정하였다.In order to investigate the protective effect of liver damage caused by chronic alcohol intake when the composition of the present invention was administered, animal experiments were carried out as follows. Negative control group and positive control group were treated with PBS (Phosphate buffered saline) for 5 ml / kg B.W. Forced oral administration was performed, and the composition group contained 5 ml / kg B.W. Administration was for 1 week. 2 g / kg B.W. alcohol with 22% alcohol solution in the positive control and composition groups within 30 minutes after PBS or Y-MIX administration on the 1st, 4th and 7th day of the test. Forced oral administration. After administration of alcohol on the 7th day of the test, heart blood was collected the next day to measure the contents of GOT, GPT, and Bilirubin in the blood. After necropsy, hepatic tissue was observed to measure the hepatic activity index expressed numerically of pathological symptoms. .
그 결과를 도4에 나타내었으며, 본 발명의 조성물의 우수한 간손상 보호효과를 알 수 있다.The results are shown in Figure 4, it can be seen the excellent liver damage protection effect of the composition of the present invention.
한편, 상기 본 발명의 조성물은 이를 유효성분으로 하고 통상적인 담체나 부형제 등을 첨가하여 각종 기능성 음료나 발효유식품, 건강보조식품 등으로 구성할 수 있다.On the other hand, the composition of the present invention can be composed of various functional beverages, fermented milk foods, health supplements and the like by adding this as an active ingredient and a conventional carrier or excipient.
이상 설명한 바와 같이, 본 발명에 따르면, 가시오가피 추출물, 갈근 추출물, 구기자 추출물, 오리목 추출물, 꿀풀 추출물, 밀크씨슬 추출물 중에서 3가지 성분이 주원료로 하고 순무 농축액, 생두-미강 발효 추출물을 부원료로 함으로써, 섭취하였을 때 알코올에 의한 간 손상을 보호 또는 치유하는 기능을 갖는 동시에 음주 후 혈중 알코올을 저하시키는 기능이 있고, 특히, 과음 또는 만성 알코올 섭취에 의한 간 손상을 보호하거나 이들에 의해 손상 받은 간을 치유하는 효과가 매우 우수하고, 음주 후 알코올 대사를 촉진하여 혈중 알코올을 저하시키는 기능이 매우 우수하여, 관련 분야에의 이용 및 응용이 기대된다 하겠다.As described above, according to the present invention, by the three components as the main raw material from the extract of prickly pear extract, brown root extract, goji berry extract, alderwood extract, nectar extract, milk thistle extract and turnip concentrate, green bean-rice bran fermentation extract as a sub raw material, It has the function of protecting or healing liver damage caused by alcohol when ingested and at the same time lowering blood alcohol after drinking alcohol, in particular, protecting the liver damage caused by excessive drinking or chronic alcohol intake or healing the liver damaged by them. The effect is very excellent, and the function of promoting alcohol metabolism after drinking to lower the blood alcohol is very excellent, the use and application in related fields is expected.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040072213A KR100655593B1 (en) | 2004-09-09 | 2004-09-09 | Composition for Liver Protection and Reduction of Serum Ethanol Level |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040072213A KR100655593B1 (en) | 2004-09-09 | 2004-09-09 | Composition for Liver Protection and Reduction of Serum Ethanol Level |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060023385A KR20060023385A (en) | 2006-03-14 |
KR100655593B1 true KR100655593B1 (en) | 2006-12-08 |
Family
ID=37129610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040072213A KR100655593B1 (en) | 2004-09-09 | 2004-09-09 | Composition for Liver Protection and Reduction of Serum Ethanol Level |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100655593B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109430640A (en) * | 2018-09-17 | 2019-03-08 | 中山市艾丽意素生物科技有限公司 | A kind of drinks of relieving alcoholism and protecting liver |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100880382B1 (en) * | 2007-01-22 | 2009-01-23 | 윤심 | Composition comprising rice bran, method for manufacturing ferment composition of rice bran therefrom, and ferment composition of rice bran thereby |
KR101113603B1 (en) * | 2011-08-05 | 2012-02-13 | (주)에쎄르 | Extract composition of herbal mixture for improving liver fucntion and relieving hangover |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020092562A (en) * | 2001-06-04 | 2002-12-12 | 정풍한방제약주식회사 | Functional beverage, tea composition and a preparation process thereof |
-
2004
- 2004-09-09 KR KR1020040072213A patent/KR100655593B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020092562A (en) * | 2001-06-04 | 2002-12-12 | 정풍한방제약주식회사 | Functional beverage, tea composition and a preparation process thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109430640A (en) * | 2018-09-17 | 2019-03-08 | 中山市艾丽意素生物科技有限公司 | A kind of drinks of relieving alcoholism and protecting liver |
Also Published As
Publication number | Publication date |
---|---|
KR20060023385A (en) | 2006-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0126431B1 (en) | Healthy food having effect of falling of blood sugar | |
KR100913243B1 (en) | A drink composition for eliminating hangover | |
KR100795822B1 (en) | Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tee including the same as effective components and the preparation method thereof | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR100373501B1 (en) | An antistress composition for a stress prevention and treatment | |
JP2002275077A (en) | Lipase inhibitor | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
KR100306427B1 (en) | Medicinal composition for diabetes | |
KR101461165B1 (en) | Hangover curing agent | |
KR101588378B1 (en) | Method for manufacturing hangover curing agent and hangover curing agent manufactured by the same | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
KR100655593B1 (en) | Composition for Liver Protection and Reduction of Serum Ethanol Level | |
KR101829810B1 (en) | Fermented composition containing both forage barley and medicinal herbs extract material, and a preparation method thereof | |
US7399491B2 (en) | Health promoting functional foods fortified with herbs | |
KR101400368B1 (en) | A composition comprising boiled powder or extract of Glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication | |
KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
US20100074975A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract | |
KR102428520B1 (en) | Manufacturing method of Liquor using Red Ginseng Concentrate, Angelica Extract, Chlorella and Perilla Frutescens Extract | |
KR102050554B1 (en) | Composition for hangover treatment and manufacturing method for the same | |
KR102165239B1 (en) | Hepatoprotective Composition Comprising Abeliophyllum Distichum Extract | |
KR101811227B1 (en) | Composition for Immune Enhancement, Fatigue Recovery, Physiologically Active, Detoxification Comprising Extracts of Lycium chinence miller, Rubus coreanus Miq. & Schisandra chinensis | |
KR20100116919A (en) | Compositions comprising extract from codonopsis lanceolata for preventing or treating obesity, hyperlipidemia or fatty liver | |
KR100846521B1 (en) | Composition comprising an extract of herbal combination(oca-i) or the powder(oca-ii) thereof for preventing and treating diabetes mellitus | |
KR20100102366A (en) | Composition of assitant healthful food | |
CN114246337B (en) | Composition for strengthening spleen, eliminating dampness and losing weight as well as preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20091203 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20111101 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141203 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151203 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161205 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181204 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191202 Year of fee payment: 14 |